ClinicalTrials.gg
CompletedNCT06006585Updated Feb 18, 2025

A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

A Phase 1 interventional study of BI 771716 in Geographic Atrophy, sponsored by Boehringer Ingelheim. Completed at 9 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-02-18.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
89th of 107
20 · median 98
Started
2023
with 11 others
Phase 1
16 of 131
3 open now
Registered
94th of 131
by date
Lead sponsor
4 of 131
Boehringer Ingelheim

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 89th largest by enrollment of the 107 interventional ones that give a count, is one of 12 that started in 2023, is one of 16 in phase 1, and was the 94th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults with geographic atrophy, an advanced form of age-related macular degeneration. People can join the study if they are at least 50 years old. The purpose of this study is to find out how well different doses of a medicine called BI 771716 are tolerated.

This study has 2 parts. Part 1 of the study takes about 3 months. In this part, participants receive 1 injection of BI 771716 directly into one of the eyes affected by geographic atrophy.

Part 2 of the study takes about 4 months. In this part, participants receive 2 injections of BI 771716 directly into the eye. There are 4 weeks between the first and the second injection. In this study, BI 771716 is given to humans for the first time.

The doctors compare how well participants tolerate the different doses of BI 771716. The doctors also regularly check the general health of the participants.

03

Conditions studied

  • Geographic Atrophy

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), with any GA lesion of minimum 1 disc diameter (minimum 2.5 mm\^2) in size, and unlimited maximum size. This may include GA lesions contiguous to or continuous with peripapillary atrophy.
  2. Fellow eye is not required to have GA.
  3. Best corrected visual acuity (BCVA) in the non-study eye must have a better BCVA compared to the study eye.
  4. BCVA of ≥4 and ≤70 letters in the study eye (approximate equivalent to 20/800 and 20/40 on the Snellen chart) measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol.
  5. Age at least 50 years.
  6. Men able to father a child must be ready and able to use highly effective methods of per the International Council on Harmonisation of Technical Requirements for Registration of Human Use guideline M3(R2) (ICH M3(R2)) that would result in a low failure rate of less than 1% per year when used consistently and correctly.
  7. Signed consistent with ICH good clinical practice (GCP) guidelines and local legislation prior to participation in the trial, which includes medication washout and restrictions.
  8. Not under any administrative or legal supervision or under institutionalization due to regulatory or juridical order.

Exclusion criteria

Exclusion Criteria:

  1. Women of (WOCBP) cannot be included. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy or another cause as determined by the investigator (e.g. Müllerian agenesis). Tubal ligation is NOT a method of permanent sterilization. A postmenopausal state is defined as no menses for 1 year without an alternative medical cause.
  2. History of or evidence of current active exudative choroidal neovascularization (CNV) in the study eye. History of evidence of exudative CNV in the fellow eye is not exclusionary. Eyes with evidence of non-exudative CNV are not exclusionary (as identified by spectral domain optical coherence tomography (SD-OCT) and fluorescein angiography (FA)) .
  3. Previously received treatment in the study eye for GA secondary to AMD within 3 months prior to screening.
  4. Previous trial participation receiving trial medication for GA in the study eye secondary to AMD within 6 months prior to screening. Use of any drug within 90 days or 5 half-lives prior to screening, whichever is longer.
  5. Previously received gene therapy or cell therapy.
  6. Additional eye disease in the study eye that could compromise trial participation:

    1. uncontrolled glaucoma or intraocular pressure >24 mmHg.
    2. diabetic maculopathy.
    3. history of high myopia >8 diopters in the study eye.
    4. anterior segment and vitreous abnormalities in the study eye that would preclude adequate observation with Spectral domain optical coherence tomography (SD-OCT).
    5. exclude ocular conditions at discretion of the investigator that might interfere with outcome of the trial.
  7. Exclude prior vitrectomy surgery.
  8. Exclude study eyes that have undergone glaucoma drainage implantation or trabeculectomy. History of microinvasive glaucoma surgery may be included.

Further exclusion criteria apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    BI 771716 low dose treatment group (Single rising dose (SRD part))

    Drug: BI 771716

  • Experimental
    BI 771716 treatment group (multiple dose (MD part))

    Drug: BI 771716

  • Experimental
    BI 771716 medium dose treatment group (SRD part)

    Drug: BI 771716

  • Experimental
    BI 771716 high dose treatment group (SRD part)

    Drug: BI 771716

Interventions

  • DrugBI 771716

    BI 771716

06

What researchers measure

Primary outcomes

  1. Occurrence of ocular dose limiting events (DLEs) from drug administration until Day 8

    SRD part

    Time frame: Up to 7 days

  2. Occurrence of drug-related adverse events (AEs) from drug administration until end of study (EOS)

    MD part

    Time frame: Up to 112 days

Secondary outcomes

  1. Occurrence of any ocular adverse events (AEs) in the study eye from drug administration until EOS

    SRD part

    Time frame: Up to 112 days

  2. Maximum serum concentration of BI 771716 after a single intravitreal (IVT) dose (Cmax)

    SRD part

    Time frame: Up to 84 days

  3. Area under the concentration-time curve of BI 771716 in serum over the time interval from 0 extrapolated to infinity (AUC0-∞)

    SRD part

    Time frame: Up to 84 days

  4. Time from dosing to maximum serum concentration of BI 771716 (tmax)

    SRD part

    Time frame: Up to 84 days

  5. Trough concentration of BI 771716 in serum

    MD part

    Time frame: At Day 29

  6. BI 771716 serum concentration

    MD part

    Time frame: At Day 57

07

Study locations

9 sites
  • Bay Area Retina Associates - Walnut Creek
    Walnut Creek, California 94598, United States
  • Florida Retina Institute
    Jacksonville, Florida 32204, United States
  • Florida Eye Associates
    Melbourne, Florida 32901, United States
  • Verum Research, LLC
    Eugene, Oregon 97401, United States
  • Erie Retina Research, LLC
    Erie, Pennsylvania 16507, United States
  • Tennessee Retina
    Nashville, Tennessee 37215, United States
  • Austin Clinical Research, LLC
    Austin, Texas 78750, United States
  • Retina Consultants of Houston, PA-Houston-62050
    Houston, Texas 77030, United States
  • Retina Consultants of Texas-The Woodlands-67575
    The Woodlands, Texas 77384, United States
08

References and documents

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in May 2024, 7 months.

Of 13 phase 1 interventional studies under Geographic Atrophy, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Aug 23, 2023
StartActual
Oct 6, 2023
Primary completionActual
May 24, 2024
CompletionActual
May 24, 2024
Last update
Feb 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06006585
Responsible party
Sponsor
First posted
Aug 23, 2023
Start date
Oct 6, 2023
Primary completion
May 24, 2024
Completion
May 24, 2024
Last update
Feb 18, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion